Combination treatment for osteoporosis
    4.
    发明授权
    Combination treatment for osteoporosis 失效
    骨质疏松症的联合治疗

    公开(公告)号:US5646137A

    公开(公告)日:1997-07-08

    申请号:US700184

    申请日:1996-08-20

    CPC分类号: A61K31/565 A61K31/57

    摘要: This invention provides a new method for treating osteoporosis comprising administering:1) a compound of formula I ##STR1## wherein R and R.sup.1, independently, are hydrogen, hydoxyl, C.sub.1 -C.sub.6 -alkoxy, C.sub.1 -C.sub.6 acyloxy, C.sub.1 -C.sub.6 alkoxy-C.sub.2 -C.sub.6 -acyloxy, R.sup.2 -substituted aryloxy, R.sup.2 -substituted aroyloxy, R.sup.3 -substituted carbonyloxy or halo;R.sup.2 is C.sub.1 -C.sub.3 -alkyl, C.sub.1 -C.sub.3 -alkoxy, hydrogen or halo; andR.sup.3 is C.sub.1 -C.sub.6 -alkoxy or aryloxy;n is 2, 3 or 4; andp is 4, 5 or 6;or a pharmaceutically acceptable salt or solvate thereof; together with2) a progestin selected from medroxyprogesterone, norethindrone or norethynodrel, or a pharmaceutically acceptable salt thereof; in amounts such that the combination retains or increases bone density.The invention also provides pharmaceutical formulations for inhibiting bone loss comprising (1)a compound of formula I, or a pharmaceutically acceptable salt or solvate thereof; and (2) a progestin selected from medroxyprogesterone, norethindrone or norethynodrel, or a pharmaceutically acceptable salt thereof; in amounts such that the combination inhibits bone loss, together with one or more pharmaceutically acceptable carriers.

    摘要翻译: 本发明提供了一种治疗骨质疏松症的新方法,包括给药:1)式Ⅰ化合物其中R和R 1独立地是氢,羟基,C 1 -C 6烷氧基,C 1 -C 6酰氧基, C6烷氧基-C2-C6-酰氧基,R2-取代的芳氧基,R2-取代的芳酰氧基,R3-取代的羰氧基或卤素; R2是C1-C3-烷基,C1-C3-烷氧基,氢或卤素; 并且R 3是C 1 -C 6 - 烷氧基或芳氧基; n为2,3或4; p为4,5或6; 或其药学上可接受的盐或溶剂化物; 以及2)选自甲羟孕酮,炔诺酮或炔诺酮的孕激素或其药学上可接受的盐; 其量使得组合保持或增加骨密度。 本发明还提供用于抑制骨丢失的药物制剂,其包含(1)式I化合物或其药学上可接受的盐或溶剂合物; 和(2)选自甲羟孕酮,炔诺酮或炔诺酮的孕激素或其药学上可接受的盐; 其量使得组合抑制骨丢失,以及一种或多种药学上可接受的载体。

    Methods for lowering serum cholesterol
    6.
    发明授权
    Methods for lowering serum cholesterol 失效
    降低血清胆固醇的方法

    公开(公告)号:US5464845A

    公开(公告)日:1995-11-07

    申请号:US159159

    申请日:1993-11-30

    摘要: A method of lowering serum cholesterol levels comprising administering to a patient a serum cholesterol lowering amount of a compound having the formula ##STR1## wherein n is 0, 1 or 2;R is hydroxyl, methoxy, C.sub.1 -C.sub.7 alkanoyloxy, C.sub.3 -C.sub.7 cycloalkanoyloxy, (C.sub.1 -C.sub.6 alkoxy)-C.sub.1 -C.sub.7 alkanoyloxy, substituted or unsubstituted aroyloxy, or substituted or unsubstituted aryloxycarbonyloxy;R.sup.1 is hydrogen, hydroxyl, chloro, bromo, methoxy, C.sub.1 -C.sub.7 alkanoyloxy, C.sub.3 -C.sub.7 cycloalkanoyloxy, (C.sub.1 -C.sub.6 alkoxy)-C.sub.1 -C.sub.7 alkanoyloxy, substituted or unsubstituted aroyloxy, or substituted or unsubstituted aryloxycarbonyloxy;R.sup.2 is a heterocyclic ring selected from the group consisting of pyrrolidino, piperidino, or hexamethyleneimino; or a pharmaceutically acceptable salt or solvate thereof.

    摘要翻译: 降低血清胆固醇水平的方法包括向患者施用血清胆固醇降低量的具有式(I)的化合物,其中n为0,1或2; R是羟基,甲氧基,C 1 -C 7烷酰氧基,C 3 -C 7环烷酰氧基,(C 1 -C 6烷氧基)-C 1 -C 7烷酰氧基,取代或未取代的芳氧基或取代或未取代的芳氧基羰基氧基; R1是氢,羟基,氯,溴,甲氧基,C1-C7烷酰氧基,C3-C7环烷酰氧基,(C1-C6烷氧基)-C1-C7烷酰氧基,取代或未取代的芳酰氧基或取代或未取代的芳氧羰基氧基; R2是选自吡咯烷子基,哌啶子基或六亚甲基亚氨基的杂环; 或其药学上可接受的盐或溶剂合物。

    Sulfonate and carbamate derivatives of 3-aroylbenzo[b] thiophenes
    10.
    发明授权
    Sulfonate and carbamate derivatives of 3-aroylbenzo[b] thiophenes 失效
    3-芳酰基苯并[b]噻吩的磺酸盐和氨基甲酸酯衍生物

    公开(公告)号:US5605924A

    公开(公告)日:1997-02-25

    申请号:US588663

    申请日:1996-01-17

    CPC分类号: C07D333/56

    摘要: The present invention relates to compounds of the formula ##STR1## where X is a bond or --CH2--;R.sup.2 is pyrrolidino;R is OH, --OSO.sub.2 --(CH.sub.2).sub.n --CH.sub.3 or ##STR2## R.sup.1 is hydrogen, OH, fluoro, chloro, --OSO.sub.2 --(CH.sub.2).sub.n --CH.sub.3 or ##STR3## each R.sup.3 is independently C.sub.1 -C.sub.6 alkyl, C.sub.3 -C.sub.6 cycloalkyl, unsubstituted or substituted phenyl where the substituent is fluoro, chloro, C.sub.1 -C.sub.3 alkyl or C.sub.1 -C.sub.3 alkoxy;each n is independently 3, 4 or 5; and pharmaceutically acceptable salts and solvates thereof; provided that at least one of R and R.sup.1 is ##STR4## The invention also relates to methods of use of the compounds of formula I and pharmaceutical compositions which comprise compounds of formula I.

    摘要翻译: 本发明涉及下式的化合物,其中X是一个键或-CH 2 - ; R2是吡咯烷子基; R是OH,-OSO 2 - (CH 2)n -CH 3或R 1是氢,OH,氟,氯,-OSO 2 - (CH 2)n -CH 3或者每个R 3独立地是C 1 -C 6烷基,C 3 C 6环烷基,未取代或取代的苯基,其中取代基是氟,氯,C 1 -C 3烷基或C 1 -C 3烷氧基; 每个n独立地为3,4或5; 及其药学上可接受的盐和溶剂合物; 条件是R和R 1中的至少一个是本发明还涉及式I化合物的使用方法和包含式I化合物的药物组合物。